Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2

被引:27
作者
Baral, Pravas Kumar [1 ]
Yin, Jiang [1 ]
James, Michael N. G. [1 ]
机构
[1] Univ Alberta, Fac Med & Dent, Dept Biochem, Edmonton, AB T6G 2H7, Canada
关键词
SARS-CoV-2; COVID-19; Antibody; Vaccine; RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; ANTIBODIES; GLYCOPROTEIN; VACCINES; BINDING; ENTRY;
D O I
10.1016/j.ijbiomac.2021.07.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Researchers from the world over are working to create prophylactic and therapeutic interventions to combat the COVID-19 global healthcare crisis. The current therapeutic options against the COVID-19 include repurposed drugs aimed at targets other than virus-specific proteins. Antibody-based therapeutics carry a lot of promise, and there are several of these candidates for COVID-19 treatment currently being investigated in the preclinical and clinical research stages around the world. The viral spike protein (S protein) appears to be the main target of antibody development candidates, with the majority being monoclonal antibodies. Several antibody candidates targeting the SARS-CoV-2 S protein include LY-CoV555, REGN-COV2, JS016, TY027, CT-P59, BRII-196, BRII-198 and SCTA01. These neutralizing antibodies will treat COVID-19 and possibly future coronavirus infections. Future studies should focus on effective immune-therapeutics and immunomodulators with the purpose of developing specific, affordable, and cost-effective prophylactic and treatment regimens to fight the COVID-19 globally.
引用
收藏
页码:490 / 500
页数:11
相关论文
共 93 条
  • [21] The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade
    Coutard, B.
    Valle, C.
    de lamballerie, X.
    Canard, B.
    Seidah, N. G.
    Decroly, E.
    [J]. ANTIVIRAL RESEARCH, 2020, 176
  • [22] COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
    Dhama, Kuldeep
    Sharun, Khan
    Tiwari, Ruchi
    Dadar, Maryam
    Malik, Yashpal Singh
    Singh, Karam Pal
    Chaicumpa, Wanpen
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1232 - 1238
  • [23] Dong Jinhui, 2021, bioRxiv, DOI 10.1101/2021.01.27.428529
  • [24] Duan K., 2020, P NATL ACAD SCI USA, V117, P9490, DOI [10.1073/PNAS.2004168117, DOI 10.1073/pnas.2004168117]
  • [25] Food and Drug Administration, BAML EM US AUTH LETT
  • [26] A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses
    Fung, Sin-Yee
    Yuen, Kit-San
    Ye, Zi-Wei
    Chan, Chi-Ping
    Jin, Dong-Yan
    [J]. EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 558 - 570
  • [27] Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective
    Hammarstrom, Lennart
    Abolhassani, Hassan
    Baldanti, Fausto
    Marcotte, Harold
    Pan-Hammarstrom, Qiang
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (01) : 58 - 60
  • [28] COVID-19: Developing from an Outbreak to A Pandemic
    Hanaei, Sara
    Rezaei, Nima
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2020, 51 (06) : 582 - 584
  • [29] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
    Hoffmann, Markus
    Kleine-Weber, Hannah
    Schroeder, Simon
    Krueger, Nadine
    Herrler, Tanja
    Erichsen, Sandra
    Schiergens, Tobias S.
    Herrler, Georg
    Wu, Nai-Huei
    Nitsche, Andreas
    Mueller, Marcel A.
    Drosten, Christian
    Poehlmann, Stefan
    [J]. CELL, 2020, 181 (02) : 271 - +
  • [30] SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
    Hou, Yixuan J.
    Chiba, Shiho
    Halfmann, Peter
    Ehre, Camille
    Kuroda, Makoto
    Dinnon, Kenneth H.
    Leist, Sarah R.
    Schafer, Alexandra
    Nakajima, Noriko
    Takahashi, Kenta
    Lee, Rhianna E.
    Mascenik, Teresa M.
    Graham, Rachel
    Edwards, Caitlin E.
    Tse, Longping, V
    Okuda, Kenichi
    Markmann, Alena J.
    Bartelt, Luther
    de Silva, Aravinda
    Margolis, David M.
    Boucher, Richard C.
    Randell, Scott H.
    Suzuki, Tadaki
    Gralinski, Lisa E.
    Kawaoka, Yoshihiro
    Baric, Ralph S.
    [J]. SCIENCE, 2020, 370 (6523) : 1464 - 1468